Printer Friendly

Cenomed BioSciences Co-Awarded Chemical Defense Grant by JSTO-CBD/DTRA to Evaluate the Use of Novel Compounds to Enhance the Effectiveness of Currently Used Nerve Agent Treatments.

- Cenomed to Collaborate with Air Force Research Laboratory, Wright-Patterson Air Force Base, and Wright State University -

IRVINE, Calif. -- Cenomed BioSciences, LLC, a majority-owned subsidiary of Abraxis BioScience, Inc. (NASDAQ:ABBI), today announced that in collaboration with co-investigators Major David Watson (Air Force Research Laboratory, Wright-Patterson Air Force Base) and Dr. James Lucot (Associate Professor of Pharmacology and Toxicology, Wright State University), it has received a three-year research and development grant from the Defense Joint Science and Technology Office for Chemical and Biological Defense (JSTO-CBD)/Threat Reduction Agency (DTRA). The grant will fund preclinical studies of selected compounds from Cenomed's library of novel chemical defense compounds with the purpose of evaluating therapeutic drug combinations as treatment following nerve agent exposure. Research emphasis will be placed on drug combinations that enhance currently approved treatments. Cenomed's compounds are being developed as a pre- and post-exposure therapy for military and civilian victims of a chemical nerve agent attack. Financial terms of the agreement were not disclosed.

"This JSTO-CBD/DTRA grant builds on Cenomed's previous successful research and will further support Cenomed's ongoing three-year cooperative research and development agreement (CRADA) with the United States Army Medical Research Institute of Chemical Defense (USAMRICD)," said David R. Helton, President, CEO and CSO of Cenomed BioSciences, LLC.

Under the grant, Cenomed plans to synthesize compounds and conduct preclinical safety studies and will supply the compounds to the Air Force Research Laboratory and Wright State University for evaluation of effectiveness following chemical warfare agent exposure.

In May 2007, Cenomed partnered with Abraxis BioScience for the development of novel therapeutics for use in chemical defense and for the treatment of nervous system disorders with a focus on psychiatric and neurological diseases. Cenomed continues to explore strategic partnership opportunities within the pharmaceutical sector for the development of novel compounds discovered by the company.

About the Defense Threat Reduction Agency

The Defense Threat Reduction Agency (DTRA) was founded in 1998 to integrate and focus the capabilities of the Department of Defense that address the weapons of mass destruction (WMD) threat. The mission of the DTRA is to safeguard America and its allies from WMD (chemical, biological, radiological, nuclear, and high yield explosives) by providing capabilities to reduce, eliminate, and counter the threat, and mitigate its effects. Under DTRA, Department of Defense resources, expertise and capabilities are combined to ensure the United States remains ready and able to address the present and future WMD threat. Please refer to USAMRICD's web site at:

About the Defense Joint Science and Technology Office for Chemical and Biological Defense

The mission of the Chemical and Biological Defense Program is to ensure that the U.S. military has the capability to operate effectively and decisively in the face of biological or chemical warfare threats at home or abroad. Numerous rapidly-changing factors continually influence the program and its management, including planning for war-fighting support to asymmetrical threats, the evolving geopolitical environment, U.S. participation in the Chemical Weapons Convention, the threat of global proliferation of chemical and biological weapons, and DoD resources available. Improved defensive capabilities are essential in order to minimize the impact of such weapons. U.S. forces require aggressive, realistic training and the finest equipment available that allows them to avoid contamination, if possible, and to protect, decontaminate and sustain operations. Further information about the DoD CBD Program (and related programs) is available at the DoD Counter proliferation and Chemical Biological Defense Homepage at WPAFB 07-0176 Unclassified.

About Cenomed BioSciences, LLC

Cenomed BioSciences, LLC, a joint venture between Abraxis BioScience, Inc. (NASDAQ:ABBI) and Cenomed, Inc., is a pharmaceutical company focused on the development of innovative new drug therapies for chemical defense and for the treatment of nervous system disorders such as schizophrenia, mild cognitive impairment and memory/attention impairments associated with aging, attention deficit hyperactivity disorder and pain. Cenomed BioScience is a majority-owned subsidiary of Abraxis BioScience, Inc. More information on Cenomed BioSciences is available at
COPYRIGHT 2007 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007, Gale Group. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Nov 5, 2007
Previous Article:Itron to Present at the UBS Global Technology & Services Conference and Stephens Fall Investment Conference.
Next Article:IKEA in Search of 125 to Join Swedish Retailer in Tacoma.

Related Articles
Pandemic planning needed in workplaces.
Using intelligent multi-agents to simulate investor behaviors in a stock market.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters